Wyeth Korea releases first-in-class antibiotic

Published: 2009-06-17 06:58:00

Updated: 2009-06-17 06:58:00

Wyeth Korea, a Korean unit of Wyeth, has launched Tygacil (tigecycline) with an expanded broad spectrum of in vitro activity against many gram positives, gram negatives, anaerobes, methicillin-resistant and -susceptible Staphylococcus aureus and vancomycin-resistant enterococci.

Tygacil is the...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK